{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:21:17Z","timestamp":1772119277710,"version":"3.50.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T00:00:00Z","timestamp":1716508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T00:00:00Z","timestamp":1716508800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"DOI":"10.1007\/s00403-024-03085-y","type":"journal-article","created":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T11:02:49Z","timestamp":1716548569000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Development of a biomarker signature associated with anoikis to predict prognosis and immunotherapy response in melanoma"],"prefix":"10.1007","volume":"316","author":[{"given":"Zhixuan","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rongrong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingxia","family":"Bao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengqi","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaowu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,24]]},"reference":[{"issue":"3","key":"3085_CR1","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.pbiomolbio.2011.09.011","volume":"107","author":"S Gandini","year":"2011","unstructured":"Gandini S, Autier P, Boniol M (2011) Reviews on sun exposure and artificial light and melanoma. Prog Biophys Mol Biol 107(3):362\u2013366. https:\/\/doi.org\/10.1016\/j.pbiomolbio.2011.09.011","journal-title":"Prog Biophys Mol Biol"},{"issue":"4","key":"3085_CR2","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1615\/CritRevEukaryotGeneExpr.2020028454","volume":"30","author":"B Ahmed","year":"2020","unstructured":"Ahmed B, Qadir MI, Ghafoor S (2020) Malignant melanoma: skin Cancer-diagnosis, Prevention, and treatment. Crit Rev Eukaryot Gene Expr 30(4):291\u2013297. https:\/\/doi.org\/10.1615\/CritRevEukaryotGeneExpr.2020028454","journal-title":"Crit Rev Eukaryot Gene Expr"},{"key":"3085_CR3","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.ejca.2022.03.008","volume":"170","author":"C Garbe","year":"2022","unstructured":"Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Basset-Seguin N et al (2022) European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022. Eur J Cancer 170:236\u2013255. https:\/\/doi.org\/10.1016\/j.ejca.2022.03.008","journal-title":"Eur J Cancer"},{"issue":"4","key":"3085_CR4","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1111\/bjd.14347","volume":"174","author":"AL Frauchiger","year":"2016","unstructured":"Frauchiger AL, Mangana J, Rechsteiner M, Moch H, Seifert B, Braun RP et al (2016) Prognostic relevance of lactate dehydrogenase and serum S100 levels in stage IV melanoma with known BRAF mutation status. Br J Dermatol 174(4):823\u2013830. https:\/\/doi.org\/10.1111\/bjd.14347","journal-title":"Br J Dermatol"},{"issue":"3","key":"3085_CR5","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s11912-017-0575-8","volume":"19","author":"S Raigani","year":"2017","unstructured":"Raigani S, Cohen S, Boland GM (2017) The role of surgery for Melanoma in an era of effective systemic therapy. Curr Oncol Rep 19(3):17. https:\/\/doi.org\/10.1007\/s11912-017-0575-8","journal-title":"Curr Oncol Rep"},{"issue":"1","key":"3085_CR6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3322\/caac.21166","volume":"63","author":"R Siegel","year":"2013","unstructured":"Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63(1):11\u201330. https:\/\/doi.org\/10.3322\/caac.21166","journal-title":"CA Cancer J Clin"},{"issue":"10304","key":"3085_CR7","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/s0140-6736(21)01206-x","volume":"398","author":"MS Carlino","year":"2021","unstructured":"Carlino MS, Larkin J, Long GV (2021) Immune checkpoint inhibitors in melanoma. Lancet 398(10304):1002\u20131014. https:\/\/doi.org\/10.1016\/s0140-6736(21)01206-x","journal-title":"Lancet"},{"issue":"1","key":"3085_CR8","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/s41392-021-00827-6","volume":"6","author":"W Guo","year":"2021","unstructured":"Guo W, Wang H, Li C (2021) Signal pathways of melanoma and targeted therapy. Signal Transduct Target Ther 6(1):424. https:\/\/doi.org\/10.1038\/s41392-021-00827-6","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"3085_CR9","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.suc.2019.09.010","volume":"100","author":"AG Wernicke","year":"2020","unstructured":"Wernicke AG, Polce S, Parashar B (2020) Role of Radiation in the era of effective systemic therapy for Melanoma. Surg Clin North Am 100(1):189\u2013199. https:\/\/doi.org\/10.1016\/j.suc.2019.09.010","journal-title":"Surg Clin North Am"},{"issue":"8","key":"3085_CR10","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/nrclinonc.2017.43","volume":"14","author":"JJ Luke","year":"2017","unstructured":"Luke JJ, Flaherty KT, Ribas A, Long GV (2017) Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat Rev Clin Oncol 14(8):463\u2013482. https:\/\/doi.org\/10.1038\/nrclinonc.2017.43","journal-title":"Nat Rev Clin Oncol"},{"key":"3085_CR11","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.canlet.2021.03.011","volume":"508","author":"HJ Han","year":"2021","unstructured":"Han HJ, Sung JY, Kim SH, Yun UJ, Kim H, Jang EJ et al (2021) Fibronectin regulates anoikis resistance via cell aggregate formation. Cancer Lett 508:59\u201372. https:\/\/doi.org\/10.1016\/j.canlet.2021.03.011","journal-title":"Cancer Lett"},{"key":"3085_CR12","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.biocel.2014.03.009","volume":"51","author":"ND Amoedo","year":"2014","unstructured":"Amoedo ND, Rodrigues MF, Rumjanek FD (2014) Mitochondria: are mitochondria accessory to metastasis? Int J Biochem Cell Biol 51:53\u201357. https:\/\/doi.org\/10.1016\/j.biocel.2014.03.009","journal-title":"Int J Biochem Cell Biol"},{"issue":"2","key":"3085_CR13","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.cellsig.2011.10.005","volume":"24","author":"X Zhong","year":"2012","unstructured":"Zhong X, Rescorla FJ (2012) Cell surface adhesion molecules and adhesion-initiated signaling: understanding of anoikis resistance mechanisms and therapeutic opportunities. Cell Signal 24(2):393\u2013401. https:\/\/doi.org\/10.1016\/j.cellsig.2011.10.005","journal-title":"Cell Signal"},{"key":"3085_CR14","doi-asserted-by":"publisher","first-page":"626577","DOI":"10.3389\/fonc.2021.626577","volume":"11","author":"FO Adeshakin","year":"2021","unstructured":"Adeshakin FO, Adeshakin AO, Afolabi LO, Yan D, Zhang G, Wan X (2021) Mechanisms for modulating Anoikis Resistance in Cancer and the relevance of metabolic reprogramming. Front Oncol 11:626577. https:\/\/doi.org\/10.3389\/fonc.2021.626577","journal-title":"Front Oncol"},{"issue":"1\u20132","key":"3085_CR15","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.cell.2014.12.033","volume":"160","author":"MS Rooney","year":"2015","unstructured":"Rooney MS, Shukla SA, Wu CJ, Getz G, Hacohen N (2015) Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160(1\u20132):48\u201361. https:\/\/doi.org\/10.1016\/j.cell.2014.12.033","journal-title":"Cell"},{"issue":"5","key":"3085_CR16","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1007\/s11010-022-04384-6","volume":"477","author":"T Shi","year":"2022","unstructured":"Shi T, Zhang C, Xia S (2022) The potential roles and mechanisms of non-coding RNAs in cancer anoikis resistance. Mol Cell Biochem 477(5):1371\u20131380. https:\/\/doi.org\/10.1007\/s11010-022-04384-6","journal-title":"Mol Cell Biochem"},{"issue":"5","key":"3085_CR17","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s10585-022-10172-9","volume":"39","author":"SU Khan","year":"2022","unstructured":"Khan SU, Fatima K, Malik F (2022) Understanding the cell survival mechanism of anoikis-resistant cancer cells during different steps of metastasis. Clin Exp Metastasis 39(5):715\u2013726. https:\/\/doi.org\/10.1007\/s10585-022-10172-9","journal-title":"Clin Exp Metastasis"},{"issue":"1","key":"3085_CR18","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1186\/s12864-022-08475-y","volume":"23","author":"Y Chen","year":"2022","unstructured":"Chen Y, Guo L, Zhou Z, An R, Wang J (2022) Identification and validation of a prognostic model for melanoma patients with 9 ferroptosis-related gene signature. BMC Genomics 23(1):245. https:\/\/doi.org\/10.1186\/s12864-022-08475-y","journal-title":"BMC Genomics"},{"key":"3085_CR19","doi-asserted-by":"publisher","first-page":"711145","DOI":"10.3389\/fimmu.2021.711145","volume":"12","author":"Y Yang","year":"2021","unstructured":"Yang Y, Li Y, Qi R, Zhang L (2021) Development and validation of a combined glycolysis and Immune Prognostic Model for Melanoma. Front Immunol 12:711145. https:\/\/doi.org\/10.3389\/fimmu.2021.711145","journal-title":"Front Immunol"},{"issue":"1","key":"3085_CR20","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1002\/1878-0261.12412","volume":"13","author":"M Riefolo","year":"2019","unstructured":"Riefolo M, Porcellini E, Dika E, Broseghini E, Ferracin M (2019) Interplay between small and long non-coding RNAs in cutaneous melanoma: a complex jigsaw puzzle with missing pieces. Mol Oncol 13(1):74\u201398. https:\/\/doi.org\/10.1002\/1878-0261.12412","journal-title":"Mol Oncol"},{"issue":"8","key":"3085_CR21","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1634\/theoncologist.2017-0677","volume":"23","author":"Z Aburjania","year":"2018","unstructured":"Aburjania Z, Jang S, Whitt J, Jaskula-Stzul R, Chen H, Rose JB (2018) The role of Notch3 in Cancer. Oncologist 23(8):900\u2013911. https:\/\/doi.org\/10.1634\/theoncologist.2017-0677","journal-title":"Oncologist"},{"issue":"11","key":"3085_CR22","doi-asserted-by":"publisher","first-page":"3451","DOI":"10.1158\/0008-5472.Can-12-3902","volume":"73","author":"H Cui","year":"2013","unstructured":"Cui H, Kong Y, Xu M, Zhang H (2013) Notch3 functions as a tumor suppressor by controlling cellular senescence. Cancer Res 73(11):3451\u20133459. https:\/\/doi.org\/10.1158\/0008-5472.Can-12-3902","journal-title":"Cancer Res"},{"issue":"1","key":"3085_CR23","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1158\/1541-7786.Mcr-14-0334","volume":"13","author":"CW Brown","year":"2015","unstructured":"Brown CW, Brodsky AS, Freiman RN (2015) Notch3 overexpression promotes anoikis resistance in epithelial ovarian cancer via upregulation of COL4A2. Mol Cancer Res 13(1):78\u201385. https:\/\/doi.org\/10.1158\/1541-7786.Mcr-14-0334","journal-title":"Mol Cancer Res"},{"issue":"2","key":"3085_CR24","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1158\/2159-8290.Cd-15-0283","volume":"6","author":"W Peng","year":"2016","unstructured":"Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff MT et al (2016) Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discov 6(2):202\u2013216. https:\/\/doi.org\/10.1158\/2159-8290.Cd-15-0283","journal-title":"Cancer Discov"},{"issue":"9","key":"3085_CR25","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1007\/s00018-011-0878-0","volume":"69","author":"AH Aguissa-Tour\u00e9","year":"2012","unstructured":"Aguissa-Tour\u00e9 AH, Li G (2012) Genetic alterations of PTEN in human melanoma. Cell Mol Life Sci 69(9):1475\u20131491. https:\/\/doi.org\/10.1007\/s00018-011-0878-0","journal-title":"Cell Mol Life Sci"},{"issue":"2","key":"3085_CR26","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1111\/j.1755-148X.2011.00950.x","volume":"25","author":"W Deng","year":"2012","unstructured":"Deng W, Gopal YN, Scott A, Chen G, Woodman SE, Davies MA (2012) Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition. Pigment Cell Melanoma Res 25(2):248\u2013258. https:\/\/doi.org\/10.1111\/j.1755-148X.2011.00950.x","journal-title":"Pigment Cell Melanoma Res"},{"issue":"21","key":"3085_CR27","doi-asserted-by":"publisher","first-page":"8736","DOI":"10.1158\/0008-5472.Can-10-0902","volume":"70","author":"YN Gopal","year":"2010","unstructured":"Gopal YN, Deng W, Woodman SE, Komurov K, Ram P, Smith PD et al (2010) Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in braf-mutant human cutaneous melanoma cells. Cancer Res 70(21):8736\u20138747. https:\/\/doi.org\/10.1158\/0008-5472.Can-10-0902","journal-title":"Cancer Res"},{"issue":"21","key":"3085_CR28","doi-asserted-by":"publisher","first-page":"8275","DOI":"10.1158\/0008-5472.Can-09-1067","volume":"69","author":"MI Vitolo","year":"2009","unstructured":"Vitolo MI, Weiss MB, Szmacinski M, Tahir K, Waldman T, Park BH et al (2009) Deletion of PTEN promotes tumorigenic signaling, resistance to anoikis, and altered response to chemotherapeutic agents in human mammary epithelial cells. Cancer Res 69(21):8275\u20138283. https:\/\/doi.org\/10.1158\/0008-5472.Can-09-1067","journal-title":"Cancer Res"},{"key":"3085_CR29","doi-asserted-by":"publisher","first-page":"27391","DOI":"10.1038\/srep27391","volume":"6","author":"AL Jeong","year":"2016","unstructured":"Jeong AL, Han S, Lee S, Park S, Lu J, Yu Y (2016) Patient derived mutation W257G of PPP2R1A enhances cancer cell migration through SRC-JNK-c-Jun pathway. Sci Rep 6:27391. https:\/\/doi.org\/10.1038\/srep27391","journal-title":"Sci Rep"},{"issue":"4","key":"3085_CR30","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1016\/j.ajpath.2011.01.009","volume":"178","author":"M Shih Ie","year":"2011","unstructured":"Shih Ie M, Panuganti PK, Kuo KT, Mao TL, Kuhn E, Jones S et al (2011) Somatic mutations of PPP2R1A in ovarian and uterine carcinomas. Am J Pathol 178(4):1442\u20131447. https:\/\/doi.org\/10.1016\/j.ajpath.2011.01.009","journal-title":"Am J Pathol"},{"key":"3085_CR31","doi-asserted-by":"publisher","unstructured":"Yilmaz A, Loustau T, Salom\u00e9 N, Surendran P, Li S, Tucker C (2022) Advances on the roles of tenascin-C in cancer. J Cell Sci 135(18). https:\/\/doi.org\/10.1242\/jcs.260244","DOI":"10.1242\/jcs.260244"},{"issue":"46","key":"3085_CR32","doi-asserted-by":"publisher","first-page":"6115","DOI":"10.1038\/onc.2010.350","volume":"29","author":"M Fukunaga-Kalabis","year":"2010","unstructured":"Fukunaga-Kalabis M, Martinez G, Nguyen TK, Kim D, Santiago-Walker A, Roesch A et al (2010) Tenascin-C promotes melanoma progression by maintaining the ABCB5-positive side population. Oncogene 29(46):6115\u20136124. https:\/\/doi.org\/10.1038\/onc.2010.350","journal-title":"Oncogene"},{"issue":"2","key":"3085_CR33","doi-asserted-by":"publisher","first-page":"821","DOI":"10.3892\/ijmm.2018.3652","volume":"42","author":"N Yoneura","year":"2018","unstructured":"Yoneura N, Takano S, Yoshitomi H, Nakata Y, Shimazaki R, Kagawa S et al (2018) Expression of annexin II and stromal tenascin C promotes epithelial to mesenchymal transition and correlates with distant metastasis in pancreatic cancer. Int J Mol Med 42(2):821\u2013830. https:\/\/doi.org\/10.3892\/ijmm.2018.3652","journal-title":"Int J Mol Med"},{"issue":"1","key":"3085_CR34","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1046\/j.1523-1747.2003.12014.x","volume":"120","author":"M Puviani","year":"2003","unstructured":"Puviani M, Marconi A, Cozzani E, Pincelli C (2003) Fas ligand in pemphigus sera induces keratinocyte apoptosis through the activation of caspase-8. J Invest Dermatol 120(1):164\u2013167. https:\/\/doi.org\/10.1046\/j.1523-1747.2003.12014.x","journal-title":"J Invest Dermatol"},{"issue":"14","key":"3085_CR35","doi-asserted-by":"publisher","first-page":"2574","DOI":"10.1016\/j.ejca.2009.04.001","volume":"45","author":"Y Liu","year":"2009","unstructured":"Liu Y, Wen QJ, Yin Y, Lu XT, Pu SH, Tian HP et al (2009) FASLG polymorphism is associated with cancer risk. Eur J Cancer 45(14):2574\u20132578. https:\/\/doi.org\/10.1016\/j.ejca.2009.04.001","journal-title":"Eur J Cancer"},{"issue":"2","key":"3085_CR36","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1172\/jci124011","volume":"129","author":"B Boisson","year":"2019","unstructured":"Boisson B, Honda Y, Ajiro M, Bustamante J, Bendavid M, Gennery AR et al (2019) Rescue of recurrent deep intronic mutation underlying cell type-dependent quantitative NEMO deficiency. J Clin Invest 129(2):583\u2013597. https:\/\/doi.org\/10.1172\/jci124011","journal-title":"J Clin Invest"},{"issue":"7","key":"3085_CR37","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1136\/gutjnl-2021-324420","volume":"71","author":"R Sundar","year":"2022","unstructured":"Sundar R, Huang KK, Kumar V, Ramnarayanan K, Demircioglu D, Her Z et al (2022) Epigenetic promoter alterations in GI tumour immune-editing and resistance to immune checkpoint inhibition. Gut 71(7):1277\u20131288. https:\/\/doi.org\/10.1136\/gutjnl-2021-324420","journal-title":"Gut"},{"issue":"6","key":"3085_CR38","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1038\/s43018-022-00382-1","volume":"3","author":"V Anagnostou","year":"2022","unstructured":"Anagnostou V, Bardelli A, Chan TA, Turajlic S (2022) The status of tumor mutational burden and immunotherapy. Nat Cancer 3(6):652\u2013656. https:\/\/doi.org\/10.1038\/s43018-022-00382-1","journal-title":"Nat Cancer"},{"issue":"7378","key":"3085_CR39","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/nature10673","volume":"480","author":"I Mellman","year":"2011","unstructured":"Mellman I, Coukos G, Dranoff G (2011) Cancer immunotherapy comes of age. Nature 480(7378):480\u2013489. https:\/\/doi.org\/10.1038\/nature10673","journal-title":"Nature"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03085-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-024-03085-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03085-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T07:30:32Z","timestamp":1719387032000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-024-03085-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,24]]},"references-count":39,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["3085"],"URL":"https:\/\/doi.org\/10.1007\/s00403-024-03085-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2916953\/v1","asserted-by":"object"}]},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,24]]},"assertion":[{"value":"21 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"219"}}